ArticleCardiovascular engineering and technology2026
A Small-Diameter Tricuspid Valve Prosthesis for the Correction of Congenital Heart Defects Based on an Adult Donor Mitral Valve Homograft.
Article in Cardiovascular engineering and technology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTricuspid valve replacement is the preferred method when valve repair is not feasible. Stented xenobioprostheses, which limit the growth of the fibrous ring due to their rigid titanium frame and often have a short service life, are particularly problematic in children. An alternative approach is the implantation of a mitral valve homograft in the tricuspid position, which is more resistant to calcification. However, the limited availability of small-diameter homografts from adult donors restricts their use. To address this, a new technique for downsizing an adult mitral homograft was developed and tested in a wet lab and in silico (using 3D printing technologies).
methodsTwo techniques for reducing the size of the mitral homograft were developed: one creating a single papillary muscle and the other creating two neo-papillary muscles. The hydrodynamics of the resulting prostheses were assessed using visual inspection and ultrasound evaluation.
resultsIt was demonstrated that reducing the mitral homograft by resecting the commissures, a portion of the anterior leaflet, and the posterior leaflet along with their subvalvular structures is a reliable method. This technique does not violate the congruence of the anterior and posterior leaflets and ensures optimal hydrodynamic parameters.
conclusionsThe proposed technique makes it possible to downsize an adult mitral homograft to a "pediatric" size. It can be used clinically as an intraoperative adaptation technique, performed on the "back table" in 30-40 minutes.
Indexed as
Identifiers
42090121What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.